ak 2123 has been researched along with Carcinoma, Squamous Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hori, H; Ito, M; Nagasawa, H; Ogino, H; Shibamoto, Y; Sugie, C; Suzuki, H; Uto, Y | 1 |
| García-Angulo, AH; Kagiya, VT | 1 |
1 trial(s) available for ak 2123 and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Intratumoral and parametrial infusion of a 3-nitrotriazole (AK-2123) in the radiotherapy of the uterine cervix cancer: stage II-III--preliminary positive results.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Evaluation; Female; Humans; Radiation-Sensitizing Agents; Triazoles; Uterine Cervical Neoplasms | 1992 |
1 other study(ies) available for ak 2123 and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Reevaluation of the radiosensitizing effects of sanazole and nimorazole in vitro and in vivo.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Evaluation, Preclinical; Female; Mice; Nimorazole; Nitroimidazoles; Radiation Tolerance; Radiation-Sensitizing Agents; Treatment Outcome; Triazoles | 2005 |